Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter

Medical Device Investing

Specialty diagnostics company Precipio (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017 of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold year-over-year from the 4th quarter of 2016 revenues of approximately $316,000. As quoted in the press release: “Now that assets have been integrated and systems …

Specialty diagnostics company Precipio (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4^th quarter of 2017 of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold year-over-year from the 4^th quarter of 2016 revenues of approximately $316,000.

As quoted in the press release:

“Now that assets have been integrated and systems optimized, we have resumed our focus on sales growth and aggressively capturing market share with our disruptive diagnostic products and services,” commented Ilan Danieli, CEO. “Our team worked around the clock to ensure resumption of services within Q3-2017, and our sales growth in Q4 reflects that hard work. We will remain completely focused on continuing this revenue growth throughout the year.”

Click here to read the full press release.

diagnostic diagnostics diagnostics company precipio Medical Device Investing